---
layout: post
title: "Notice; Licensing and Collaboration Opportunity"
date: 2026-02-05 18:56:30 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-17673
original_published: 2023-08-17 00:00:00 +0000
significance: 8.00
---

# Notice; Licensing and Collaboration Opportunity

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** August 17, 2023 00:00 UTC
**Document Number:** 2023-17673

## Summary

The invention listed below is directed to potential peptidyl therapeutics that counteract with amyloid forming IAPP and amyloid- [beta] in treatments of diabetes and Alzheimer's disease and serve as blood-based biomarkers for Alzheimer's disease. This technology was discovered and is being developed by the National Institute on Aging (NIA). The NIA is currently seeking a licensee and/or collaborator to further develop this technology.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/08/17/2023-17673/notice-licensing-and-collaboration-opportunity)
- API: https://www.federalregister.gov/api/v1/documents/2023-17673

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
